The identification of glyco-form profile in BCG-resistant bladder cancer and the creation of therapeutic drug using nanoparticle BCG
| Project/Area Number |
24592372
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Hirosaki University |
|---|
Principal Investigator |
Mori Kazuyuki 弘前大学, 医学研究科, 助教 (40266903)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
大山 力 弘前大学, 医学研究科, 教授 (80282135)
|
|---|
| Research Collaborator |
YANO IKUYA 日本ビーシージー製造株式会社, 研究開発顧問(研究職)
|
|---|
| Project Period (FY) |
2012-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
|---|
| Keywords | BCG / ナノパーティクルBCG / 糖鎖構造解析 / 膀胱癌 |
|---|
| Outline of Final Research Achievements |
Intravesical BCG therapy is effective treatment for non-muscle invasive bladder cancer, however, BCG failure and side effect through live bacterial infection are remaining. In this study, the model of BCG failure were developed by continuous co-culture of tumor cell lines with live BCG. The change of BCG strain (e.g. Tokyo 172 strain to Connaught strain) was effective against BCG resistant cells, however, cells became double resistant shortly. Nanoparticle BCG was effective against BCG double resistant cells. These results suggested that the sequential therapy, the change of BCG strain, and then nanoparticle BCG, might be effective in clinical setting.
|
Report
(6 results)
Research Products
(26 results)
-
[Journal Article] Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer2017
Author(s)
Hagiwara K, Tobisawa Y, Kaya T, Kaneko T, Hatakeyama S, Mori K, Hashimoto Y, Koie T, Suda Y, Ohyama C, Yoneyama T
-
Journal Title
Int J Mol Sci
Volume: 18(2)
Pages: 261-276
Related Report
Peer Reviewed
-
-
[Journal Article] Core 2 β-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimen is an indicator of prostate cancer aggressiveness.2016
Author(s)
Sato T, Yoneyama T, Tobisawa Y, Hatakeyama S, Yamamoto H, Kojima Y, Mikami J, Mori K, Hashimoto Y, Koie T, Ohyama C.
-
Journal Title
Biochem Biophys Res Commun.
Volume: ４０７
Issue: 1
Pages: 150-6
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
-
[Journal Article] Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.2015
Author(s)
Koie T, Ohyama C, Hosogoe S, Yamamoto H, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Yoneyama T, Tobisawa Y, Mori K.
-
Journal Title
Int Urol Nephrol
Volume: 47(9)
Issue: 9
Pages: 1509-14
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer.2014
Author(s)
Yoneyama T, Ohyama C, Hatakeyama S, Narita S, Habuchi T, Koie T, Mori K, Hidari KI, Yamaguchi M, Suzuki T, Tobisawa Y
-
Journal Title
Biochem Biophys Res Commun.
Volume: 448
Issue: 4
Pages: 390-396
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Outcome Comparison of ABO-Incompatible Kidney Transplantation With Low-Dose Rituximab and ABO-Compatible Kidney Transplantation: A Single-Center Experience.2014
Author(s)
Hatakeyama S, Fujita T, Murakami R, Suzuki Y, Sugiyama N, Yamamoto H, Okamoto A, Imai A, Tobisawa Y, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Koie T, Narumi S, Ohyama C.
-
Journal Title
Transplant Proc.
Volume: 46
Issue: 2
Pages: 445-448
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity2013
Author(s)
Okamoto, T., Sutoh Yoneyama, M.,Hatakeyama, S., Mori, K., Yamamoto, H.,Koie, T., Saitoh, H., Yamaya, K., Funyu,T., Fukuda, M., Ohyama, C. and Tsuboi,S.
-
Journal Title
Molecular Medicine Reports
Volume: 7
Issue: 2
Pages: 359-364
DOI
Related Report
Peer Reviewed
-
-
-
[Presentation] BCG菌株交替療法についての基礎的検討と耐性化メカニズムの解析2016
Author(s)
盛 和行, 飛澤 悠葵, 米山 徹, 岩村 大径, 佐藤 天童, 藤田 尚紀, 三上 穣太郎, 今井 篤, 畠山 真吾, 米山 高弘, 橋本 安弘, 古家 琢也, 大山 力
Organizer
第104回日本泌尿器科学学会総会
Place of Presentation
仙台国際会議場 他（宮城県仙台市）
Year and Date
2016-04-22
Related Report
-
[Presentation] BCG生菌double耐性株に対するナノパーティクルBCGの直接効果2016
Author(s)
盛 和行, 米山 徹, 野呂 大輔, 成田 拓磨, 田中 壽和, 萩原 和久, 及川 真亮, 今井 篤, 畠山 真吾, 米山 高弘, 橋本 安弘, 古家 琢也, 大山 力
Organizer
第9回BCG注入療法研究会
Place of Presentation
ベルサール東京日本橋（東京都中央区）
Related Report
-
-
-
-
-
-
-
-
[Presentation] Nanoparticle BCG has identical direct antitumor effect as live BCG, but has adifferent antitumor mechanism．2012
Author(s)
Mori K, Yoneyama T, Tobisawa Y, Ishibashi Y, Murasawa H, Hatakeyama S, Kudo S, Yoneyama T, Koie T, Kamimura N, Ohyama C
Organizer
第107回米国泌尿器科学会（AUA）
Place of Presentation
アトランタ
Related Report
-
-
-
